195 related articles for article (PubMed ID: 34537245)
1. Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction.
Ahmad J; Jiang J; Boyd LF; Zeher A; Huang R; Xia D; Natarajan K; Margulies DH
J Biol Chem; 2021 Oct; 297(4):101202. PubMed ID: 34537245
[TBL] [Abstract][Full Text] [Related]
2. Structures of synthetic nanobody-SARS-CoV-2-RBD complexes reveal distinct sites of interaction and recognition of variants.
Ahmad J; Jiang J; Boyd LF; Zeher A; Huang R; Xia D; Natarajan K; Margulies DH
Res Sq; 2021 Jun; ():. PubMed ID: 34159326
[TBL] [Abstract][Full Text] [Related]
3. Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes.
Ahmad J; Jiang J; Boyd LF; Natarajan K; Margulies DH
bioRxiv; 2021 Jan; ():. PubMed ID: 33532775
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
[TBL] [Abstract][Full Text] [Related]
5. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
Koenig PA; Das H; Liu H; Kümmerer BM; Gohr FN; Jenster LM; Schiffelers LDJ; Tesfamariam YM; Uchima M; Wuerth JD; Gatterdam K; Ruetalo N; Christensen MH; Fandrey CI; Normann S; Tödtmann JMP; Pritzl S; Hanke L; Boos J; Yuan M; Zhu X; Schmid-Burgk JL; Kato H; Schindler M; Wilson IA; Geyer M; Ludwig KU; Hällberg BM; Wu NC; Schmidt FI
Science; 2021 Feb; 371(6530):. PubMed ID: 33436526
[TBL] [Abstract][Full Text] [Related]
6. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
Li T; Cai H; Yao H; Zhou B; Zhang N; van Vlissingen MF; Kuiken T; Han W; GeurtsvanKessel CH; Gong Y; Zhao Y; Shen Q; Qin W; Tian XX; Peng C; Lai Y; Wang Y; Hutter CAJ; Kuo SM; Bao J; Liu C; Wang Y; Richard AS; Raoul H; Lan J; Seeger MA; Cong Y; Rockx B; Wong G; Bi Y; Lavillette D; Li D
Nat Commun; 2021 Jul; 12(1):4635. PubMed ID: 34330908
[TBL] [Abstract][Full Text] [Related]
7. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
Asarnow D; Wang B; Lee WH; Hu Y; Huang CW; Faust B; Ng PML; Ngoh EZX; Bohn M; Bulkley D; Pizzorno A; Ary B; Tan HC; Lee CY; Minhat RA; Terrier O; Soh MK; Teo FJ; Yeap YYC; Seah SGK; Chan CEZ; Connelly E; Young NJ; Maurer-Stroh S; Renia L; Hanson BJ; Rosa-Calatrava M; Manglik A; Cheng Y; Craik CS; Wang CI
Cell; 2021 Jun; 184(12):3192-3204.e16. PubMed ID: 33974910
[TBL] [Abstract][Full Text] [Related]
8. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.
Yang L; Li J; Guo S; Hou C; Liao C; Shi L; Ma X; Jiang S; Zheng B; Fang Y; Ye L; He X
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829998
[TBL] [Abstract][Full Text] [Related]
10. Binding of synthetic nanobodies to the SARS-CoV-2 receptor-binding domain: the importance of salt bridges.
Shen H; Yang H
Phys Chem Chem Phys; 2023 Sep; 25(35):24129-24142. PubMed ID: 37655617
[TBL] [Abstract][Full Text] [Related]
11. Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.
Rattanapisit K; Bulaon CJI; Khorattanakulchai N; Shanmugaraj B; Wangkanont K; Phoolcharoen W
PLoS One; 2021; 16(8):e0253574. PubMed ID: 34379620
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
13. Molecular Basis of Mink ACE2 Binding to SARS-CoV-2 and Its Mink-Derived Variants.
Su C; He J; Han P; Bai B; Li D; Cao J; Tian M; Hu Y; Zheng A; Niu S; Chen Q; Rong X; Zhang Y; Li W; Qi J; Zhao X; Yang M; Wang Q; Gao GF
J Virol; 2022 Sep; 96(17):e0081422. PubMed ID: 36000849
[TBL] [Abstract][Full Text] [Related]
14. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.
Wang WB; Liang Y; Jin YQ; Zhang J; Su JG; Li QM
J Mol Graph Model; 2021 Dec; 109():108035. PubMed ID: 34562851
[TBL] [Abstract][Full Text] [Related]
15. Cryo-EM structure determination of small proteins by nanobody-binding scaffolds (Legobodies).
Wu X; Rapoport TA
Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34620716
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of hippopotamus ACE2 binding to SARS-CoV-2.
Yang R; Han P; Han P; Li D; Zhao R; Niu S; Liu K; Li S; Tian W-X; Gao GF
J Virol; 2024 May; 98(5):e0045124. PubMed ID: 38591877
[TBL] [Abstract][Full Text] [Related]
17. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike.
Schoof M; Faust B; Saunders RA; Sangwan S; Rezelj V; Hoppe N; Boone M; Billesbølle CB; Puchades C; Azumaya CM; Kratochvil HT; Zimanyi M; Deshpande I; Liang J; Dickinson S; Nguyen HC; Chio CM; Merz GE; Thompson MC; Diwanji D; Schaefer K; Anand AA; Dobzinski N; Zha BS; Simoneau CR; Leon K; White KM; Chio US; Gupta M; Jin M; Li F; Liu Y; Zhang K; Bulkley D; Sun M; Smith AM; Rizo AN; Moss F; Brilot AF; Pourmal S; Trenker R; Pospiech T; Gupta S; Barsi-Rhyne B; Belyy V; Barile-Hill AW; Nock S; Liu Y; Krogan NJ; Ralston CY; Swaney DL; García-Sastre A; Ott M; Vignuzzi M; ; Walter P; Manglik A
Science; 2020 Dec; 370(6523):1473-1479. PubMed ID: 33154106
[TBL] [Abstract][Full Text] [Related]
18. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
[TBL] [Abstract][Full Text] [Related]
19. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.
Custódio TF; Das H; Sheward DJ; Hanke L; Pazicky S; Pieprzyk J; Sorgenfrei M; Schroer MA; Gruzinov AY; Jeffries CM; Graewert MA; Svergun DI; Dobrev N; Remans K; Seeger MA; McInerney GM; Murrell B; Hällberg BM; Löw C
Nat Commun; 2020 Nov; 11(1):5588. PubMed ID: 33149112
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of severe acute respiratory syndrome coronavirus 2 infection.
Ge J; Zhang S; Zhang L; Wang X
Curr Opin HIV AIDS; 2021 Jan; 16(1):74-81. PubMed ID: 33186231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
